A novel inhibitor of the growth and proliferation of breast cancer stem cells (CSC) discovered in a phenotypic screen employing CSC-like cells produced by inducing human breast epithelial cells into an epithelial-to-mesenchymal transdifferentiated state (HMLE_sh_ECad). ML239 displayed an...
Know who made it. See the evidence. Buy through one marketplace.
A novel inhibitor of the growth and proliferation of breast cancer stem cells (CSC) discovered in a phenotypic screen employing CSC-like cells produced by inducing human breast epithelial cells into an epithelial-to-mesenchymal transdifferentiated state (HMLE_sh_ECad). ML239 displayed an IC50=1.18 μM against HMLE_sh_ECad and demonstrated a >23-fold selectivity over control cells. It was also toxic to two other CSC-like lines. Gene expression studies showed altered gene expression in the NFκB pathway and support activation of fatty acid desaturase 2 (FADS2) as a potential mechanism of action for ML239
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
